Current practices for treatment of respiratory syncytial virus and other non‐influenza respiratory viruses in high‐risk patient populations: a survey of institutions in the Midwestern Respiratory Virus Collaborative

Abstract

Treatment of RSV in immunocompromised patients varied greatly. While most centers treat LRTI, treatment of URTI was variable. No consensus was found regarding the use of oral versus inhaled RBV, or the use of IVIG. The presence of such heterogeneity demonstrates the need for further studies defining optimal treatment of RSV in immunocompromised hosts.